It's not chemotherapy. It's targeted treatment called radioligand therapy (RLT) for PSMA+ mCRPC.

The FIRST and ONLY RLT for PSMA+ mCRPC

RLT is a different type of radiation therapy that is injected or infused and targets a biomarker called PSMA.

Remember it in 3 steps

PLUVICTO is designed to find and attack PSMA+ cells. PSMA is found on many prostate cancer cells and also some healthy cells.

When PLUVICTO finds PSMA on the surface of a cell, it goes into the cell.

Once inside, PLUVICTO releases radiation, damaging or destroying the cell from within. It may also affect some nearby healthy cells.